Recombinant Zebrafish ADCYAP1B

• Cat.No.: ADCYAP1B-8281Z
• Product Overview: Recombinant Zebrafish ADCYAP1B full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: adcyap1b adenylate cyclase activating polypeptide 1b [ Danio rerio (zebrafish) ]
• Official Symbol: ADCYAP1B
• Gene ID: 335625
• mRNA Refseq: NM_001272081
• Protein Refseq: NP_001259010
• UniProt ID: Q5XJ02

Q&As

Has ADCYAP1B protein therapy been approved by regulatory agencies for any conditions?

ADCYAP1B protein therapy has not yet been approved by regulatory agencies for any clinical applications. However, several PACAP analogs are currently in clinical trials for the treatment of various conditions, including migraines and anxiety disorders.

How is ADCYAP1B administered in therapeutic settings?

ADCYAP1B is typically administered as PACAP analogs, which are synthetic compounds that mimic the activity of the natural peptide. They can be administered through various routes, including intravenous injection, nasal spray, and subcutaneous injection.

How can ADCYAP1B be used to treat migraines?

ADCYAP1B has been shown to play a role in the regulation of pain and migraine headaches. PACAP analogs that mimic the activity of ADCYAP1B have been developed as potential therapeutics for migraines. These analogs can inhibit the release of calcitonin gene-related peptide (CGRP), which is involved in the development of migraines. Clinical trials have shown promising results in the treatment of acute migraines and as a prophylactic treatment for chronic migraines.

How is ADCYAP1B protein therapy administered in the treatment of migraines?

ADCYAP1B protein therapy is administered through intravenous injection, nasal spray, or subcutaneous injection. The frequency and dosage of administration may vary depending on the patient's specific condition and response to treatment.

Is ADCYAP1B protein therapy effective for all types of migraines?

ADCYAP1B protein therapy has shown promising results in the treatment of both chronic and episodic migraines. However, more research is needed to determine its effectiveness for different types of migraines, such as migraines with aura or menstrual migraines.

What other conditions have been investigated for potential treatment with ADCYAP1B protein therapy?

Aside from migraine headaches, anxiety disorders, and depression, ADCYAP1B protein therapy has been investigated for potential applications in various other conditions, including cardiovascular disease, inflammation, autoimmune disorders, and cancer.

What are the potential side effects of ADCYAP1B protein therapy for migraines?

Side effects of ADCYAP1B protein therapy may include injection site reactions, dizziness, nausea, and fatigue. However, side effects are generally mild and resolve quickly.

Are there any limitations to the use of ADCYAP1B protein therapy?

One limitation of ADCYAP1B protein therapy is that it may not be effective for all patients or all conditions. Additionally, the long-term safety and efficacy of taking this therapy need to be determined through further research. Additionally, the cost and availability of the therapy may be a limiting factor for some patients.

Is ADCYAP1B protein therapy a first-line treatment for migraines?

ADCYAP1B protein therapy is not currently a first-line treatment for migraines. It is considered a second-line or adjunct treatment option for patients who have not responded to or cannot tolerate standard treatments such as triptans, analgesics, and preventive medications.

Are there any side effects or risks associated with ADCYAP1B protein therapy?

The potential side effects and risks of ADCYAP1B protein therapy are not yet fully understood but may include headache, nausea, and fatigue. Long-term safety and efficacy studies are needed to determine the risks and benefits of ADCYAP1B protein therapy. Additionally, individual patient factors such as age, health status, and medication use may influence the safety and efficacy of treatment.

Can ADCYAP1B be used to treat anxiety disorders?

ADCYAP1B has been shown to play a role in the regulation of anxiety and may have potential therapeutic applications in anxiety disorders. Animal studies have shown that PACAP analogs can reduce anxiety-like behavior in models of anxiety disorders. Clinical trials are underway to investigate their potential as therapeutics in humans.

How can ADCYAP1B be used to treat depression?

ADCYAP1B has been shown to play a role in the regulation of mood and depressive symptoms. PACAP analogs have been shown to improve depressive symptoms in animal models of depression. Clinical trials are underway to investigate their potential as therapeutics in humans.

What are the potential benefits of ADCYAP1B protein therapy for migraine sufferers?

The potential benefits of ADCYAP1B protein therapy in migraine treatment include the reduction of migraine frequency, severity, and duration, as well as the improvement of associated symptoms such as nausea and sensitivity to light and sound.

What are the potential therapeutic applications for ADCYAP1B protein?

ADCYAP1B protein has potential therapeutic applications in various conditions, including neurological and psychiatric disorders such as migraine headaches, anxiety disorders, and depression. Additionally, it has been investigated for potential applications in cardiovascular disease, inflammation, and cancer.